Completed PHASE4 NCT00194675

TRADE-Testosterone Replacement and Dutasteride Effectiveness

Testosterone Replacement and Dutasteride Effectiveness (TRADE)

Sponsor: GlaxoSmithKline

Conditions Benign Prostatic Hyperplasia Hypogonadism

Interventions Dutasteride Placebo dutasteride Testosterone gel

Updated 6 times since 2017 Last updated: Oct 30, 2017 Started: Mar 31, 2005 Primary completion: Apr 30, 2010 Completion: Dec 31, 2010

Listed as NCT00194675, this PHASE4 trial focuses on Benign Prostatic Hyperplasia and Hypogonadism and remains completed. Sponsored by GlaxoSmithKline, it has been updated 6 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Mar 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
Seattle Institute for Biomedical and Clinical Research
Solvay Pharmaceuticals
University of Washington
VA Office of Research and Development

Data source: University of Washington

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seattle, United States